In addition, our results suggesting that one dose plus prior infection provides a higher level of protection than two doses without prior infection are consistent with laboratory studies demonstrating higher concentrations of serum RBD-specific and spike protein-specific IgG antibodies following a single mRNA dose in previously infected individuals compared to those without prior infection who have received two mRNA doses47–50. Here, CHMP5 is linked to infection.